with Stability to Dehydropeptidase I

Size: px
Start display at page:

Download "with Stability to Dehydropeptidase I"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 99, p. 5- Vol. 33, No /9/005-0$0.00/0 Copyright C 99, American Society for Microbiology In Vitro Antibacterial Activity of, a Carbapenem Antibiotic with Stability to Dehydropeptidase I JEFFREY R. EDWARDS,* PHILIP J. TURNER, CHRISTINE WANNOP, ERICA S. WITHNELL, AMANDA J. GRINDEY, AND KEVIN NAIRN Antibiotic Development Group, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SKIO TG, England Received July 9/Accepted November 9, a new carbapenem antibiotic, was demonstrated to have potent antibacterial activity against a broad spectrum of aerobes, including Staphylococcus aureus, beta-hemolytic streptococci, Streptococcus pneumoniae, Haemophilus influenzae, Neisseria spp., members of the family Enterobacternaceae, Pseudomonas spp., and gram-positive and gram-negative anaerobes in a collection of,0 unselected clinical isolates. At a concentration of,lg/ml, inhibited 90% of these strains. The spectkrum of activity of ceftazidiine and cefotaxime was more limited, and many of the Enterobacteriaceae and Pseudomonas spp. were resistant to these agentsv, piperacillin, or gentamncin. A collection of ofloxacin-resistant strains was inhibited by or imipenem at,ug/ml. was more active than metronidazole and clindamycin against anaerobes. Of the carbapenems, inipenem had greater activity against staphylococci, but was much more active against Haemophius, BranhameUa, and Neisseria spp. and all genera of Enterobacteriaceae tested. The MIC of for 90% of these strains ranged from <0.00 to,ug/ml. When tested against strains of Pseudomonas aeruginosa, inhibited 76% at,ug/ml but imipenem inhibited only 5% at this concentration. Both carbapenems exhibited similar activities against Bacteroides spp., but was more active than hinipenem against Clostridium spp. The MBC of was most commonly the same as or twice the MIC. and imipenem showed excellent activities against bacteria elaborating chromosome- or plasmid-mediated,b-lactamases, including those conferring resistance to broad-spectrum cephalosporins. The activity of was generally unaffected by the culture nmedium used, ph, 5% human serum, and inoculum size, but the susceptibility of Xanthomonas maltophilia was medium dependent., (R,5S,6S)-3-[(3S,5S)-5-dimethylcarbamoylpyrrolidin-3-ylthio] -6-[(R)--hydroxyethyl]--methyl-7-oxo-- azabicyclo[3..0]hept--ene--carboxylic acid, is a new carbapenem antibiotic. The chemical structure is presented in Fig.. Published information on is limited to structureactivity relationships (M. Sunagawa, H. Matsumura, T. Inoue, M. Fukasawa, and M. Kato, Program Abstr. 7th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 75, 97), activity against clinical isolates from Japan (M. Fukasawa, Y. Sumita, E. Tada, and T. Okuda, 7th ICAAC, abstr. no. 753, 97), activity against imipenem-resistant Pseudomonas aeruginosa (J. R. Edwards and C. Wannop, 7th ICAAC, abstr. no. 75, 97), affinities for penicillinbinding proteins and morphological changes (Y. Sumita, M. Fukasawa, and T. Okuda, 7th ICAAC, abstr. no. 756, 97), activity in vivo (T. Okuda, M. Fukasawa, T. Tanio, Y. Sumita, E. Tada, and T. Yukimatsu, 7th ICAAC, abstr. no. 757, 97), and animal pharmacokinetics and stability in vitro to renal dehydropeptidase I (T. Tanio, H. Nouda, E. Tada, T. Kohzuki, M. Kato, M. Fukasawa, T. Okuda, and S. Kamidono, 7th ICAAC, abstr. no. 75, 97). These data differentiated from imipenem on the basis of stability to human renal dehydropeptidase I, greater activity against gram-negative aerobes, and activity against imipenem-resistant P. aeruginosa. This investigation was made to compare the in vitro activity of with that of imipenemn and other selected agents (results were presented in part previously [J. R. Edwards, P. J. Turner, E. S. Withnell, and K. Nairn, 7th ICAAC, abstr. no. 755, 97]). The influence of miscella- * Corresponding author. 5 neous factors on antibacterial activity, the MBC, and the activity of against bacterial strains elaborating chromosome- or plasmid-mediated,b-lactamases were also examined. MATERIALS AND METHODS Antibiotics. was supplied by Sumitomo Pharmaceuticals Co. Ltd., Japan. All other antibiotics were obtained from commercial sources. The compounds included were imipenem, ceftazidime, cefotaxime, piperacillin, and gentamicin. and clindamycin were also tested against anaerobes, and methicillin and vancomycin were included when testing methicillin-resistant staphylococci. A commercially available combination of imipenem and cilastatin (Zienam, MSD) was used as the source of imipenem. Great care was taken to establish equivalence with a reference sample of imipenem and to show that the presence of cilastatin had no effect on the antibacterial activity of imipenem (3; unpublished observations). Bacterial strains. The clinical isolates tested were obtained mostly from hospitals in the United Kingdom since 93. This collection of,0 strains was unselected but contained many which were resistant to P-lactam antibiotics or gentamicin. MICs for members of the family Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp. of gentamicin (>,ug/ml), cefotaxi-me or ceftazidime (>,ug/ml), or piperacillin (>6 jxg/ml) were identified, and results were also analyzed separately. Further clinical isolates, elaborating plasmidmediated resistance to broad-spectrum cephalosporins or resistance to ofloxacin, were supplied by Danielle Sirot and G. Seibert, respectively. Laboratory strains elaborating characterized,-lactamases and derepresssed mutants overproducing their type I,B-

2 EDWARDS ET AL. OHCH3 H H CON ' < ~ ~ _/>P CH3 0 N COOH NH FIG.. Chemical structure of. lactamase () were tested for susceptibilities to, imipenem, and ceftazidime. A collection of 30 laboratory and reference strains of aerobic and anaerobic bacteria was used in tests to assess the influence of miscellaneous factors on the antibacterial activity of. This number was increased to 97 by the addition of clinical isolates when the MBC was determined. These strains were distributed as follows: 6 Staphylococcus aureus (methicillin susceptible), 5 coagulase-negative staphylococci (methicillin susceptible), 5 Enterococcus faecalis, 57 members of the Enterobacteriaceae ( species), 5 Acinetobacter spp., 7 P. aeruginosa, 5 Pseudomonas cepacia, Xanthomonas maltophilia, and 6 Bacteroides spp. Antimicrobial susceptibility tests. The majority of MICs were determined by the agar dilution technique by using Iso-Sensitest agar (IST) (Oxoid Ltd., London, England) with 5% horse blood added for fastidious organisms or anaerobes. Each antibiotic was prepared freshly in phosphate buffer ( M, ph 7.0) prior to use, and all MICs, with the exception of studies of inoculum effect, were determined by using an inoculum estimated by reference to an opacity standard to be 0 CFU per inoculum spot. Results were noted after overnight incubation at 37 C in an appropriate environment. Tests that included nonenteric streptococci or Haemophilus, Neisseria, or Branhamella spp. were incubated in 5% C0, and anaerobes were incubated in an atmosphere of 0% carbon dioxide and 90% hydrogen. The MIC was defined as the smallest concentration of antibiotic that prevented visible growth; a haze at the point of inoculation or one discrete colony was ignored. MBCs. MBCs were determined for 97 strains. MICs were first defined by the broth dilution technique with IST broth for aerobes and Wilkins-Chalgren broth for anaerobes. The bacterial inoculum (final) was 05 CFU/ml for both aerobes and anaerobes, judged by reference to an opacity standard. The MIC (micrograms per milliliter) was recorded after overnight incubation in an appropriate environment; the endpoint was no visible growth. The MBC was then determined by placing subculture from tubes with no growth, from the MIC range, onto agar plates and observing for growth after overnight incubation. The subculture included a dilution of /0, as an attempt to minimize carry-over of antibacterial activity, and the MBC was defined as the lowest compound concentration which reduced the starting inoculum by.3 logo; reduction in numbers was assessed by viable counts. ANTIMICROB. AGENTS CHEMOTHER. Studies of effects of miscellaneous factors on activity. The influence of human serum on MICs was assessed by using IST agar to which 0 or 5% of heat-inactivated pooled human serum had been added, and the effect of ph was assessed by using IST agar which had been adjusted during preparation to ph 6, 7, or. The influence of inoculum size was assessed by using a bacterial challenge of 0, 05, or 06 CFU per inoculum spot, again on IST agar. The following agar media were compared for use in MIC tests. Iso- Sensitest (Oxoid), Mueller-Hinton (Difco Laboratories, Detroit, Mich.), and Diagnostic Sensitivity Test (Oxoid) agars, each with and without 5% horse blood, were used in tests including both aerobes and anaerobes, and Wilkins-Chalgren and Brucella Base agars (Oxoid) plus 5% horse blood were used for anaerobes only. RESULTS AND DISCUSSION Activity against clinical isolates. The susceptibilities of the,0 unselected clinical isolates to and comparator agents are presented in Table. At,ug/ml, inhibited 90% of the strains of methicillin-susceptible S. aureus, and at,ug/ml it inhibited 90% of the methicillinresistant strains tested. Coagulase-negative staphylococci were a little less susceptible. was more active against staphylococci, the difference being greatest with methicillin-resistant strains. However, the therapeutic usefulness of any P-lactam antibiotic against methicillin-resistant strains of staphylococci may be questioned even if in vitro MICs are low (6). Nonenteric streptococci were very susceptible to all of the antibiotics tested; at,ug/ml inhibited 00% of 0 strains tested. E. faecalis was less susceptible; or imipenem at,ug/ml inhibited 00% of the strains, and piperacillin was the most active comparator. The nutritionally fastidious bacteria Haemophilus influenzae, Branhamella catarrhalis, and Neisseria spp. were more susceptible to than to imipenem. at,ug/ml was -fold more potent than imipenem against H. influenzae and at.0.00,ug/ml was -fold more potent than imipenem against B. catarrhalis and Neisseria meningitidis. At,ug/ml, inhibited most isolates of Escherichia coli, Citrobacter diversus, Citrobacterfreundii, Klebsiella pneumoniae, Klebsiella aerogenes, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Morganella morganii, and Providencia spp. It was generally - to 3-fold more potent than imipenem. and gentamicin were the least potent of the comparator agents. All of the strains of Pseudomonas spp. tested were inhibited by at,ug/ml. The strains of P. aeruginosa were more susceptible to than to imipenem; 76% were inhibited by at pug/ml, but only 5% were inhibited by this concentration of imipenem. The numbers of the other Pseudomonas spp. tested were small; within the group of 7 strains tested, 9 strains of P. cepacia were inhibited by at or,ug of imipenem per ml. at,ug/ml inhibited 90% of the strains, but cefotaxime, piperacillin, and gentamicin were much less potent. All strains of Acinetobacter calcoaceticus were inhibited by at,ug/ml. (,Lg/ml) inhibited these strains, but the comparator agents were nmuch less active. was more active than metronidazole or clindamycin against Bacteroides fragilis subsp. fragilis and other Bacteroides spp. Against these species, and imipenem exhibited similar activites, but at.,ug/ml was at least eightfold more active than imipenem against Clostridium perfringens. at,ug/ml inhibited all strains of Clostridium difficile and at,ug/ml inhibited all Peptostreptococcus strains tested. This collection of,0 strains proved to contain many which were resistant to one or more of the comparator agents. Among members of the Enterobacteriaceae, there were 3 strains which showed resistance to broad-spectrum

3 VOL. 33, 99 IN VITRO ACTIVITY OF 7 Organism (no. tested) TABLE. Staphylococcus aureus (9) Staphylococcus aureus, methicillin resistant (0) Staphylococci, coagulase negative (73) Staphylococci, coagulase negative, methicillin resistant () Streptococcus pneumoniae (30) Streptococcus group A () Streptococcus agalactiae () Streptococcus equi () Streptococcus group G (5) Enterococcus faecalis () Activities of and comparator agents against,0 unselected clinical isolates Antibiotic Vancomycin Methicillin Vancomycin Methicillin Cefotazime MIC (Lg/ml)a Range 50% 90% > so ( > s < > -> - _0.00 _< _0.00 _0.00 _ _0.00 _ _0.00 _ _0.00 _ _ > > 3 > Continued on following page

4 EDWARDS ET AL. Organism (no. tested) Haemophilus influenzae () Branhamella catarrhalis (3) Neisseria gonorrhoeae () Neisseria meningitidis (3) Escherichia coli () Citrobacter diversus (0) Citrobacterfreundii () Klebsiella pneumoniae (9) Klebsiella aerogenes (33) Klebsiella oxytoca (35) TABLE -Continued Antibiotic Ceftotaxime ANTIMICROB. AGENTS CHEMOTHER. MIC (WLg/ml)a Range 50% 90% < <0.00- <0.00- < < <0.00- <0.00- <0.00- <0.00- <0.00- <0.00- < <0.00- < <0.00- <0.00- <0.00-> < > -> > - -> -> > -> > > < > 6 Continued on following page

5 VOL. 33, 99 Organism (no. tested) Enterobacter cloacae (70) Enterobacter aerogenes () Serratia marcescens (59) Proteus mirabilis (9) Proteus vulgaris (0) Morganella morganii (0) Providencia spp. (5)b Pseudomonas aeruginosa () Pseudomonas spp. (7)C TABLE -Continued Antibiotic Ceftotaxime IN VITRO ACTIVITY OF 9 MIC (,Lg/ml)a Range. 50% 90% - - -> -> -> > > a< _0.00-> -> -> - -> - ' _ > > Continued on following page

6 0 EDWARDS ET AL. ANTIMICROB. AGENTS CHEMOTHER. Organism (no. tested) Xanthomonas maltophilia (5) Acinetobacter calcoaceticus subsp. anitratus (39) Bacteroides fragilis (56) Bacteroides spp. ()d Clostridium perfringens (5) Clostridium difficile () Peptostreptococcus spp. (0) TABLE -Continued AniitcMIC (,ug/mly' AntRb5otic Range 50%o 90% < > < < < > -6 <- <- -> -6 -> - ->.-.- -> < <- < -.- '- s-.- < <- <-.- s- - a 50% and 90%, MIC for 50 and 90%o of isolates, respectively. b Providencia alcalifaciens (n = ) and P. stuartii (n = 3). c Pseudomonas putida (n = 3), P. cepacia (n = 9), P. fluorescens (n = ), P. stutzeri (n = ), and P. acidivorans (n = ). d Bacteroides vulgatus (n = ), B. distasonis (n = 9), B. thetaiotaomicron (n = 7), and B. ovatus (n = ). 3 > s s. s s S s > 6 > 6 > 3 6 > 3 s 6 3 cephalosporins, 66 which were resistant to piperacillin, and 5 which were resistant to gentamicin, all of which were inhibited by or imipenem at,ug/ml. Resistance to the other P-lactam antibiotics and gentamicin was seen most commonly among Enterobacter cloacae; K. oxytoca was also frequently resistant to gentamicin. There were, 3, and 9 strains of Acinetobacter spp. which were resistant to the cephalosporins, piperacillin, and gentamicin, respectively; all were inhibited by or imipenem at,ug/ml. Among the strains of P. aeruginosa tested, resistance to cefotaxime was recorded frequently. Seven ceftazidimeresistant strains were inhibited by at,ug/ml, piperacillin-resistant strains were inhibited by at,ug/ml, and 9 gentamicin-resistant strains were inhibited by at,ug/ml. The comparable results for imipenem were,, and,ug/ml, respectively. A further collection of

7 VOL. 33, 99 IN VITRO ACTIVITY OF TABLE. Activities of and imipenem against strains encoding plasmid-mediated resistance to broad-spectrum cephalosporins Strain 3-Lactamase MIC (jig/ml) specified Escherichia coli 90 TEM-3 (CTX-) 0.0 Klebsiella aerogenes 076 TEM-3 (CTX-) 0.0 Enterobacter aerogenes 07 TEM-3 (CTX-) 3 Serratia marcescens 0 TEM-3 (CTX-) 3 Klebsiella aerogenes 077 TEM-5 (CAZ-) Escherichia coli ATCC clinical isolates resistant to broad-spectrum cephalosporins or ofloxacin was tested also. Four strains harboring plasmids encoding the TEM-3 (CTX-) P-lactamase and one encoding TEM-5 (CAZ-) were all inhibited by at jig/ml or by imipenem at,ug/ml (Table ). Members of the Enterobacteriaceae elaborating plasmid-mediated resistance to broad-spectrum cephalosporins are being reported with increasing frequency in Europe (, 5). Twenty ofloxacinresistant strains (five S. aureus, three Klebsiella spp., five Serratia spp., two Acinetobacter spp., and five P. aeruginosa) were inhibited by or imipenem at jig/ml. Activity against,l-lactamase-producing strains. and imipenem showed excellent activities against S. aureus, Enterobacteriaceae, and P. aeruginosa strains elaborating plasmid- or chromosome-mediated P-lactamases. was active against many of these strains but showed reduced activity against the Escherichia coli elaborating the OXA- enzyme and very poor activity (MIC,.3,ug/ml) against Enterobacteriaceae or P. aeruginosa strains derepressed for their chromosomally encoded type I P-lactamases (Table 3). Bactericidal activity. The MBC was defined for and imipenem against a collection of 97 strains comprising aerobic and anaerobic bacteria. The results, expressed as a multiple of the MIC, show that for most strains the MBC was the same as or twice the MIC of each compound (Table ). Values which were greater than twice the MIC were randomly distributed throughout the genera tested. Effects of miscellaneous factors on activity. The presence of 0 or 5% of human serum, a medium ph of 6, 7, or, or a bacterial challenge of 0, 05, or 06 CFU per inoculum spot did not significantly alter MICs of. Results were generally within the range of experimental error, and no trends were noted. An exception was seen in tests including X. maltophilia, the susceptibility of which was influenced by the choice of culture medium. When tested on Diagnostic TABLE 3. Activities of, imipenem, and ceftazidime against bacteria elaborating plasmid- or chromosome-encoded 3-lactamases Strain,-Lactamase specified MIC (,ug/ml) Staphylococcus aureus 7N PC 0.0 Escherichia coli J TEM- TEM- OXA- OXA- OXA-3 SHV- HMS- 0.0 Pseudomonas aeruginosa PU PSE- PSE- PSE-3 PSE- Pseudomonas aeruginosa S (I+) I Pseudomonas aeruginosa SH (DR)' I 6 Citrobacterfreundii 00 (I') I 0.0 Citrobacterfreundii 03 (DR) I Enterobacter cloacae 09 (I+) I Enterobacter cloacae 0 (DR) I 3 Klebsiella oxytoca 055 Klebsiella oxytoca 056 IVc a Spontaneous mutants with derepressed (DR) expression of type I (I+),-lactamase, derived from corresponding wild-type inducible parents.

8 EDWARDS ET AL. Antibiotic TABLE. MBCs of and imipenem expressed as multiples of the MIC No. of strains for which MBC is (multiple of MIC): Sensitivity Test agar, most strains were inhibited by SM- 733 at,ug/ml; on Mueller-Hinton agar, typical MICs were > jig/ml; and on IST agar, results ranged from.0.00 to,ug/ml. was inactive against of the 5 strains irrespective of the medium used. The initial report () showing the activity of imipenem against almost all clinically significant aerobic and anaerobic bacteria has been confirmed in numerous other publications. Results presented here for are in close agreement with those of Fukasawa et al. (7th ICAAC) and show that this new carbapenem has a spectrum of activity comparable to that of imipenem but with notable differences in activity against H. influenzae, B. catarrhalis, N. meningitidis, and members of the Enterobacteriaceae. These differences, primarily in potency, could assume significance if the pharmacokinetics of the two compounds are similar. The enhanced ANTIMICROB. AGENTS CHEMOTHER. activity against P. aeruginosa is the subject of further studies. ACKNOWLEDGMENTS We are indebted to T. D. Hennessey for critical reading of the manuscript and to Bev Hoult for the final presentation. LITERATURE CITED. Bauernfeind, A., and G. Horl. 97. Novel R-factor borne,blactamase of Escherichia coli conferring resistance to cephalosporins. Infection 5: Curtis, N. A. C., R. L. Eisenstadt, C. Rudd, and A. J. White. 96. Inducible type I P-lactamases of Gram-negative bacteria and resistance to,-lactam antibiotics. J. Antimicrob. Chemother. 7: Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. 93. Thienamycin: development of imipenem-cilastatin. J. Antimicrob. Chemother. (Suppl D):-35.. Kropp, H., J. S. Kahan, F. M. Kahan, and J. Birnbaum. 90. MK07 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob. Agents Chemother. 7: Labia, R., A Morand, M. Guionie, M. Heitz, and J. S. Pitton. 96. P-lactamases de Klebsiella oxytoca: etude de leur action sur les cephalosporins de troisieme generation. Pathol. Biol. 3: Thornsbury, C. 9. The development of antimicrobial resistance in staphylococci. J. Antimicrob. Chemother. (Suppl. C):9-. Downloaded from on April 0, 09 by guest

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone

More information

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases 4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

In Vitro Activity of DR-3355, an Optically Active Ofloxacin

In Vitro Activity of DR-3355, an Optically Active Ofloxacin ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1988, p. 1336-1340 0066-4804/88/091336-05$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 32, No. 9 In Vitro Activity of, an Optically Active

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities

Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland

More information

Antibacterial Spectrum

Antibacterial Spectrum ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1992, p. 1894-1901 0066-4804/92/091894-08$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 9 In Vitro and In Vivo Antibacterial Activities

More information

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

C&W Three-Year Cumulative Antibiogram January 2013 December 2015 C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time) Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according

More information

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

More information

microbiology testing services

microbiology testing services microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

Evaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli

Evaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

In Vitro and In Vivo Antibacterial Activities of T-3761, a New Quinolone Derivative

In Vitro and In Vivo Antibacterial Activities of T-3761, a New Quinolone Derivative ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1993, p. 384-392 0066-4804/93/030384-09$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 3 In Vitro and In Vivo Antibacterial Activities

More information

on February 12, 2018 by guest

on February 12, 2018 by guest AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

BSAC standardized disc susceptibility testing method (version 8)

BSAC standardized disc susceptibility testing method (version 8) Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility

More information

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Vitek QC Sets. Vitek 2 Identification QC Sets

Vitek QC Sets. Vitek 2 Identification QC Sets Vitek 2 Identification QC Sets MicroBioLogics is selling two types of Vitek 2 microorganism identification sets. They are listed below in two columns. The first column lists the 2008 quality control microorganisms

More information

C.D.S. USERS GROUP. NEWSLETTER No. 3. Report of the CDS Users Group Workshop held at the. ASM Gold Coast Meeting 1991

C.D.S. USERS GROUP. NEWSLETTER No. 3. Report of the CDS Users Group Workshop held at the. ASM Gold Coast Meeting 1991 THE PRINCE OF WALES HOSPITAL The Prince of Wales Hospital, Cnr. High & Avoca Streets, Randwick. N.S.W. 2031. SMB/BG 20 th August, 1991. Dear Colleague, C.D.S. USERS GROUP NEWSLETTER No. 3 Report of the

More information

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Leveraging the Lab and Microbiology Department to Optimize Stewardship Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

with Other Orally Administered Drugs

with Other Orally Administered Drugs ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1983, p. 209-215 0066-4804/83/080209-07$00/0 Copyright C 1983, American Society for Microbiology Vol. 24, No. 2 In Vitro Evaluation of Three New Macrolide Antimicrobial

More information

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.** Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,

More information

Antimicrobial Resistance Strains

Antimicrobial Resistance Strains Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

In Vitro Activity of Piperacillin, a New Semisynthetic Penicillin with an Unusually Broad Spectrum of Activity

In Vitro Activity of Piperacillin, a New Semisynthetic Penicillin with an Unusually Broad Spectrum of Activity ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, March 1978, p. 349-357 66-484/8/133-349$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 3 Printed in U.S.A. In Vitro Activity of Piperacillin, a

More information

Determination of antibiotic sensitivities by the

Determination of antibiotic sensitivities by the Journal of Clinical Pathology, 1978, 31, 531-535 Determination of antibiotic sensitivities by the Sensititre system IAN PHILLIPS, CHRISTINE WARREN, AND PAMELA M. WATERWORTH From the Department of Microbiology,

More information

Drug Class Prior Authorization Criteria Intravenous Antibiotics

Drug Class Prior Authorization Criteria Intravenous Antibiotics Drug Class Prior Authorization Criteria Intravenous Antibiotics Line of Business: Medicaid P&T Approval Date: August 15, 2018 Effective Date: October 1, 2018 This drug class prior authorization criteria

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

Spectrum Cephalosporin with Antipseudomonal Activity

Spectrum Cephalosporin with Antipseudomonal Activity ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1983, p. 195-200 Vol. 23, No. 2 00664804/83/020195S06$02.00/0 Copyright C 1983, American Society for Microbiology In Vitro Antibacterial Activity of, a New Broad-

More information

Bacteriological Characterization

Bacteriological Characterization ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1978, p. 414-419 0066-4804/78/0014-0414$02.00/O Copyright X) 1978 American Society for Microbiology Vol. 14, No. 3 Printed in U.S.A. CP-45,899, a Beta-Lactamase

More information

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

More information

In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea

In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea J Korean Med Sci 2002; 17: 737-42 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea Gemifloxacin is

More information

Beta-lactamase Inhibitors May Induce Resistance to Beta-lactam Antibiotics in Bacteria Associated with Clinical Infections Bhoj Singh

Beta-lactamase Inhibitors May Induce Resistance to Beta-lactam Antibiotics in Bacteria Associated with Clinical Infections Bhoj Singh Noto-are 14947537: Medicine. 2018-06-03. Beta-lactamase Inhibitors May Induce Resistance to Beta-lactam Antibiotics in Bacteria Associated with Clinical Infections Bhoj Singh Indian Veterinary Research

More information

Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae

Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and

More information

coverage. The purpose of this study was to compare the susceptibility of 297 strains of anaerobic and a new broad-spectrum semisynthetic

coverage. The purpose of this study was to compare the susceptibility of 297 strains of anaerobic and a new broad-spectrum semisynthetic ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1978, p. 643-649 0066-4804/78/0014-0643$02.00/0 Copyright 1978 American Society for Microbiology Vol. 14, No. 5 Printed in U.S.A. Susceptibility of the Anaerobic

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA

More information

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America RAPID DETECTION OF BACTERIAL CONTAMINANTS IN PLATELET COMPONENTS: COMPARISON OF TIME TO DETECTION BETWEEN THE BACT/ALERT 3D AND THE BACT/ALERT VIRTUO SYSTEMS. 17June2017 Parampal Deol, Ph.D, MBA Senior

More information

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms

Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective

More information

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Cipro for gram positive cocci in urine

Cipro for gram positive cocci in urine Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

Epidemiology and Microbiology of Surgical Wound Infections

Epidemiology and Microbiology of Surgical Wound Infections JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical

More information

IV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)

IV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.15 Subject: IV Antibiotics Lyme Disease Page: 1 of 9 Last Review Date: November 30, 2018 IV Antibiotics

More information

Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients

Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients

More information

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching

More information

Factors affecting plate assay of gentamicin

Factors affecting plate assay of gentamicin Journal of Antimicrobial Chemotherapy (1977) 3, 17-23 Factors affecting plate assay of gentamicin II. Media D. C. Shanson* and C. J. Hince Department of Medical Microbiology, The London Hospital Medical

More information

Mechanism of antibiotic resistance

Mechanism of antibiotic resistance Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Reassessment of the "Class" Concept of Disk Susceptibility Testing

Reassessment of the Class Concept of Disk Susceptibility Testing Reassessment of the "Class" Concept of Disk Susceptibility Testing Disks versus Minimal Inhibitory Concentrations with Eleven Cephalosporins ARTHUR L. BARRY, PH.D., CLYDE THORNSBERRY, PH.D., RONALD N.

More information

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance

More information

available. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory

available. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory ANTimICROBIAL AGENTh AND CHEMOTHERAPY, OCt. 1976, p. 677-681 Copyright 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. In Vitro Susceptibility of Gentamicin-Resistant Enterobacteriaceae

More information

Aminothiazolyl oc-methoxyimino Cephalosporin

Aminothiazolyl oc-methoxyimino Cephalosporin ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1984, p. 710-718 0066-4804/84/060710-09$00/0 Copyright 1984, American Society for Microbiology Vol. 25, No. 6 In Vitro Evaluation of, a New Wide-Spectrum Aminothiazolyl

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,

More information

High Antibiotic Resistance Pattern Observed in Bacterial Isolates from a Tertiary Hospital in South East Nigeria

High Antibiotic Resistance Pattern Observed in Bacterial Isolates from a Tertiary Hospital in South East Nigeria International Journal of Research in Pharmacy and Biosciences Volume 3, Issue 1, February 2016, PP 1-6 ISSN 2394-5885 (Print) & ISSN 2394-5893 (Online) High Antibiotic Resistance Pattern Observed in Bacterial

More information

Comparison of antibiotic susceptibility results obtained with Adatab* and disc methods

Comparison of antibiotic susceptibility results obtained with Adatab* and disc methods J Clin Pathol 1984;37:159-165 Comparison of antibiotic susceptibility results obtained with Adatab* and disc methods JJS SNELL, MVS DANVERS, PS GARDNER From the Division of Microbiological Reagents and

More information

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

ln-vitro activity of newer quinolones against aerobic bacteria

ln-vitro activity of newer quinolones against aerobic bacteria Journal of Antimicrobial Chemotherapy (96) 7, Suppl. B, 9-39 ln-vitro activity of newer quinolones against aerobic bacteria R. Anckenthaler, M. Michea-Hamzehponr and J. C. Pectere Laboratoire Central de

More information

VLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05

VLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05 Topic J05: Determination of susceptibility of bacteria to antimicrobial drugs, assessments of resistance factors For study: textbooks, www, keywords e. g. Diffusion disc test ; E-test ; dilution micromethod

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus TEST REPORT TEST TYPE: Liquid Suspension Time Kill Study -Quantitative Test Based On ASTM 2315 TEST METHOD of Colloidal Silver Product at Contact time points: 30 sec, 1 min, 2 min, 5 min, 10 min, 15 min

More information